Expression of serum IL-26 and its diagnostic value in patients with gastric cancer
XU Bin-bin1， CHEN Zhi-hong2， WANG Chao1， WEI Fa-xing3
(1. School of Medicine, Jiangsu University, Zhenjiang Jiangsu 212013; 2. Department of Gastroenterology, the Affiliated People′s Hospital of Jiangsu University, Zhenjiang Jiangsu 212002; 3. Department of Emergency, the Affiliated Hospital of Jiangsu University, Zhenjiang Jiangsu 212003, China)
Abstract：Objective： To explore the expression of serum IL-26 in patient with gastric cancer and its diagnostic value. Methods： A total of 176 patients with gastric cancer(cancer group) and 176 healthy person(control group) were enrolled in the study. Levels of serum IL26 and carcinoembryonic antigen(CEA), CA199, CA242, CA724 in two groups were determined by ELISA. ROC statistical diagnostic test were used to explore the clinical diagnostic value of IL26 and compared with serum tumor markers. Results： The expression level of IL-26 in gastric cancer group was significantly higher than that in control group(P<0.05). The area under the ROC curve of IL-26 was 0.956, the 95% confidence interval was 0.909-0.958. The diagnostic sensitivity was 79.2%, the diagnostic specificity was 87.4%(P=0.007); the diagnostic sensitivity and specificity of IL-26 was higher than CEA, CA199, CA242, CA724. Conclusion： Patients with gastric cancer showed high levels of serum IL-26, which could be used to improve the diagnostic efficacy of gastric cancer.
许彬彬1， 陈志红2， 汪超1， 魏法星3. 胃癌患者外周血IL-26的水平及其诊断价值[J]. 江苏大学学报:医学版, 2016, 26(05): 429-432.
XU Bin-bin1， CHEN Zhi-hong2， WANG Chao1， WEI Fa-xing3. Expression of serum IL-26 and its diagnostic value in patients with gastric cancer. Journal of Jiangsu University(Medicine Edition), 2016, 26(05): 429-432.
［1］王琼，孙巍，张春荣，等. 血清肿瘤标志联合检测在胃癌诊断中的应用\[J\]. 中华肿瘤杂志，2000，22(2):150.［2］Gao ZL, Zhang C, Du GY, et al. Clinical significance of changes in tumor markers, extracellular matrix, MMP9 and VEGF in patients with gastric carcinoma\[J\]. Hepatogastroenterology, 2007, 54(77): 1591-1595.［3］Luzza F, Parrello T, Monteleone G, et al. Upregulation of IL17 is associated with bioactive IL8 expression in Helicobacter pyloriinfected human gastric mucosa\[J\]. J Immunol, 2000, 165(9):5332-5337.［4］Selgrad M, Bornschein J, Rokkas T, et al. Clinical aspects of gastric cancer and Helicobacter pyloriscreening, prevention, and treatment\[J\]. Helicobacter, 2010, 15（Suppl 1）:40-45.［5］Iida T, Iwahashi M, Katsuda M, et al. Tumorinfiltrating CD4+ Th17 cells produce IL17 in tumor microenvironment and promote tumor progression in human gastric cancer\[J\]. Oncol Rep, 2011, 25(5):1271-1277.［6］Zhang B, Rong G, Wei H, et al. The prevalence of Th17 cells in patients with gastric cancer\[J\]. Biochem Biophys Res Commun, 2008, 374(3):533-537.［7］Chen JG, Xia JC, Liang XT, et al. Intratumoral expression of IL17 and its prognostic role in gastric adenocarcinoma patients\[J\]. Int J Biol Sci, 2011, 7(1):53-60.［8］Shibata T, Tahara T, Hirata I, et al. Genetic polymorphism of interleukin17A and 17F genes in gastric carcinogenesis\[J\]. Hum Immunol, 2009, 70(7):547-551.［9］Schaeffer EM. Re: IL17 expression by macrophages is associated with proliferative inflammatory atrophy lesions in prostate cancer patients\[J\]. J Urol, 2012, 188(1):123.［10］李巧霞，李清靖，刘艳军，等. Th17细胞及其相关细胞因子在胃癌中的表达及临床意义\[J\]. 肿瘤学杂志，2015，21(9)：708-713.［11］You W, Tang Q, Zhang C, et al. IL26 promotes the proliferation and survival of human gastric cancer cells by regulating the balance of STAT1 and STAT3 activation\[J\]. PLoS One, 2013, 8(48): e63588.［12］Zhang B, Rong G, Wei H, et al. The prevalence of Th17 cells in patients with gastric cancer\[J\]. Biochem Biophys Res Commun, 2008, 374(3): 533-537.［13］Yamada Y, Saito H, Ikeguchi M.Prevalence and clinical relevance of Th17 cells in patients with gastric cancer\[J\]. J Surg Res, 2012, 178(2):685-691.［14］Yoon SI, Jones BC, Logsdon NJ, et al. Structure and mechanism of receptor sharing by the IL10R2 common chain\[J\]. Structure, 2010, 18(5):638-648.［15］Sheikh F, Baurin VV, LewisAntes A, et al. Cutting edge: IL26 signals through a novel receptor complex composed of IL20 receptor 1 and IL10 receptor 2\[J\]. J Immunol, 2004, 172(4):2006-2010.［16］Yoon SI, Logsdon NJ, Sheikh F, et al. Conformational changes mediate interleukin10 receptor 2 (IL10R2) binding to IL10 and assembly of the signaling complex\[J\]. J Biol Chem, 2006, 281(46):35088-35096.［17］侯嘉杰，孙倍成. STAT3：慢性炎症介导肿瘤发生和进展的关键节点\[J\]. 生物化学与生物物理进展，2014,(1)：69-78.
2016, Vol. 26 
